Efficacy and Safety of Jaktinib in Patients With Severe Novel Noronavirus Pneumonia

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.

Inclusion Criteria:18 years of age, male or female;The subject was diagnosed with novel coronavirus pneumonia;It meets the heavy-duty standards of the new coronavirus pneumonia diagnosis and treatment protocol (version 9).Those who voluntarily sign informed consent.The National Institute of Allergy and Infectious Diseases Sequential Scale (NIAID-0S) score is 5 or 6;Exclusion Criteria:Those who cannot take orally, or are suspected to be allergic to Jaktinib, similar drugs or their excipients, or have severe gastrointestinal dysfunction that affects drug absorption;Those who have received the following treatments within the specified time window before randomization:They have received Janus kinase (JAK) inhibitor, interleukin 6 (IL-6) inhibitor, IL-1 inhibitor, tumor necrosis factor (TNF) inhibitor, T cell or B cell depletion agent, interferon and other immunosuppressive drugs within the first two weeks of randomization, except glucocorticoid;Systematically used CYP 3A4 potent inhibitor or potent inducer in the first five drug half lives at random;Immune deficiency;